US equities |
SPCX $166.81 ▲+4.94% NVDA $236.14 ▲+0.94% MU $1,062.61 ▼-1.14% TSLA $377.61 ▲+1.89% MSFT $524.72 ▲+1.39% SNDK $1,704.84 ▼-0.88% INTC $117.13 ▼-1.84% META $742.49 ▲+1.98%
FinancialContent

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

82.25 -0.68 (-0.82%)
Delayed Quote Updated: 12:21 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
11 Analysts Have This to Say About Mirum Pharmaceuticals ↗
 
Via Benzinga
News headline image
Mirum Pharmaceuticals Presents New Data at The Liver Meeting®
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Analyst Ratings for Mirum Pharmaceuticals ↗
 
Via Benzinga
News headline image
Earnings Outlook For Mirum Pharmaceuticals ↗
 
Via Benzinga
News headline image
Analyst Ratings for Mirum Pharmaceuticals ↗
 
Via Benzinga
News headline image
Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Present New Data at The Liver Meeting®
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Analyst Ratings for Mirum Pharmaceuticals ↗
 
Via Benzinga
News headline image
Where Mirum Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 ↗
 
Via Benzinga
News headline image
Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
7 Small-Cap Stocks That Get the Nod from Wall Street ↗
Although small-cap stocks tend to be extremely risky, these compelling ideas just happen to get the nod from Wall Street analysts. 
Via InvestorPlace
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Why Shares of Travere Therapeutics Are Slumping Thursday ↗
A mixed trial could hurt a kidney drug's chances of full approval. 
Via The Motley Fool
News headline image
Mirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2023 ↗
 
Via Benzinga
News headline image
Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Around $4M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗
Although U.S. stocks closed mostly lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >